Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-039400
Filing Date
2025-08-11
Accepted
2025-08-11 08:50:18
Documents
1
Period of Report
2025-07-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1754916614.html 4  
1 FORM 4 wk-form4_1754916614.xml 4 35132
  Complete submission text file 0001628280-25-039400.txt   36542
Mailing Address 1207 17TH AVENUE SUITE 103 NASHVILLE TN 37212
Business Address
KAZIMI A J (Reporting) CIK: 0001075050 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 251200381

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)